Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease  

作　　者：Nerea Gómez de San José Steffen Halbgebauer Petra Steinacker Sarah Anderl-Straub Samir Abu-Rumeileh Lorenzo Barba Patrick Oeckl Giovanni Bellomo Lorenzo Gaetani Andrea Toja Sára Mravinacová Sofia Bergström Anna Månberg Alberto Grassini Innocenzo Rainero Peter Nilsson Lucilla Parnetti Markus Otto 

机构地区：[1]Department of Neurology,Ulm University Hospital,Albert-Einstein-Allee 23,89081 Ulm,Germany [2]Department of Neurology,University Clinic,University Hospital Halle,Martin Luther University,Ernst-Grube Strasse 40,06120 Halle(Saale),Germany [3]Section of Neurology,Department of Medicine and Surgery,University of Perugia,Piazza dell’Università,1,06123 Perugia,Italy [4]Department of Neuroscience,“Rita Levi Montalcini”,University of Torino,Via Cherasco 15,10126 Turin,Italy [5]Department of Protein Science,SciLifeLab,KTH Royal Institute of Technology,Brinellvägen 8,11428 Stockholm,Sweden [6]German Center for Neurodegenerative Diseases(DZNE),Oberer Eselsberg 45,89081 Ulm,Germany

出　　处：《Translational Neurodegeneration》2024年第1期215-218,共4页转化神经变性病(英文)

基　　金：MO,LP,PN SM and NGSJ are supported by the Marie Skłodowska-Curie grant agreement No.860197—MIRIADE project(European Union’s Horizon 2020 research and innovation program);GB is supported by the Postdoctoral Fellowship for Basic Scientists grant of the Parkinson’s Foundation(Award ID:PF-PRF-934916);LP and LG are funded by the European Union—Next Generation EU—PNRR M6C2—Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN(PNRR-MAD-2022–12376035);LB is supported by the Medical Faculty of Martin-Luther University Halle Wittenberg(Junior Clinician Scientist Programm No.JCS24/02);SAB received research support from the Medical Faculty of Martin-Luther University Halle-Wittenberg(Clinician Scientist-Programm No.CS22/06).

摘　　要：The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].However,it is clear nowadays that alterations other than Aβand tau deposition,e.g.,blood-brain-barrier(BBB)impairment[2]and impaired protein clearance[3],may take place in early disease stages,before consistent neu-rodegeneration occurs.Therefore,additional CSF bio-markers are needed.

关 键 词：CEREBROSPINAL fluid ALZHEIMER TAU diagnosis Aβ 

分 类 号：R749.16[医药卫生—神经病学与精神病学]